NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Free peptide testing

Ordered Retatrutide from NextGen Health? Mail in a sample (US only) and let us test it for free.

Test my supply
79%
Finnrick rating
#166 of 378 Retatrutide vendors
2 of 2 classifiable tests passed
natural 100% · customers 4.6★ (1)
methodology · Purity focus
Finnrick analysis · Retatrutide

NextGen Health's evidence is strong but narrow, with Tirzepatide showing consistent identity, 99.68–99.81% purity, and fill variance within the method's tolerance. The signal is recent yet based on a small single-product run, and missing batch IDs on earlier reports limit confidence beyond Tirzepatide.

methodology →
vendor intelligence report
Vendor Intelligence Report: NextGen Health

Florida filings and archive captures tie the storefront to a named operator while undercutting its claimed history. The report also maps COA provenance, a sister fitness brand and referral-code promotion that often reads like organic community chatter.

22 pages5 risk factors assessed13 Jun 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Tirzepatide
$1.17
82%
4
2
Retatrutideselected
$1.60
79%
2
3
Melanotan II
$2.50
-
0
4
Wolverine
$1.90
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%4 Sept 2025: 71%4 Nov 2025: 77%29 Sept 2026: current 79%71%79%Sep 25Sep 26
Showing Retatrutide tests only
NextGen Health Retatrutide test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
4 Nov 2025Pass
Tested
lab nameView COA
4 Sep 2025Pass
Tested
lab nameView COA

About NextGen Health test results from Finnrick

NextGen Health is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 2 peptides and 6 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible NextGen Health peptides in this dataset are Retatrutide (2 tests), Tirzepatide (4 tests) and Melanotan II (0 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 6 recent tests.

Corrections
No corrections.
Free peptide testing

Ordered Retatrutide from NextGen Health? Mail in a sample (US only) and let us test it for free.

Test my supply